{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:11:19Z","timestamp":1789578679354,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-30521-4","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:52:26Z","timestamp":1774263146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cerebrospinal fluid and plasma metabolites in Parkinson\u2019s disease: a Mendelian randomization study"],"prefix":"10.1038","volume":"16","author":[{"given":"Jia-Li","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianhui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"30521_CR1","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.cell.2020.06.026","volume":"182","author":"E Pasciuto","year":"2020","unstructured":"Pasciuto, E. et al. Microglia require CD4 T cells to complete the fetal-to-adult transition. Cell 182, 625\u2013640e24. https:\/\/doi.org\/10.1016\/j.cell.2020.06.026 (2020).","journal-title":"Cell"},{"key":"30521_CR2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36470","author":"V Brochard","year":"2008","unstructured":"Brochard, V. et al. Infiltration of CD4\u2009+\u2009lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. JCI36470. https:\/\/doi.org\/10.1172\/JCI36470 (2008).","journal-title":"J. Clin. Invest. JCI36470"},{"key":"30521_CR3","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey, E. R., Sherer, T., Okun, M. S. & Bloem, B. R. The emerging evidence of the Parkinson pandemic. JPD 8, S3\u2013S8. https:\/\/doi.org\/10.3233\/JPD-181474 (2018).","journal-title":"JPD"},{"key":"30521_CR4","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3233\/JPD-191829","volume":"10","author":"G Yahalom","year":"2020","unstructured":"Yahalom, G. et al. Age at onset of Parkinson\u2019s disease among Ashkenazi Jewish patients: contribution of environmental factors, LRRK2 p.G2019S and GBA p.N370S mutations. JPD 10, 1123\u20131132. https:\/\/doi.org\/10.3233\/JPD-191829 (2020).","journal-title":"JPD"},{"key":"30521_CR5","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/genes12081278","volume":"12","author":"PP Chairta","year":"2021","unstructured":"Chairta, P. P. et al. Prediction of Parkinson\u2019s disease risk based on genetic profile and established risk factors. Genes 12, 1278. https:\/\/doi.org\/10.3390\/genes12081278 (2021).","journal-title":"Genes"},{"key":"30521_CR6","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s12035-021-02657-7","volume":"59","author":"X Li","year":"2022","unstructured":"Li, X., Fan, X., Yang, H. & Liu, Y. Review of metabolomics-based biomarker research for Parkinson\u2019s disease. Mol. Neurobiol. 59, 1041\u20131057. https:\/\/doi.org\/10.1007\/s12035-021-02657-7 (2022).","journal-title":"Mol. Neurobiol."},{"key":"30521_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3233\/JPD-140389","volume":"4","author":"M Trupp","year":"2014","unstructured":"Trupp, M. et al. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson\u2019s disease. J. Parkinson\u2019s Disease. 4, 549\u2013560. https:\/\/doi.org\/10.3233\/JPD-140389 (2014).","journal-title":"J. Parkinson\u2019s Disease"},{"key":"30521_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13024-021-00425-8","volume":"16","author":"Y Shao","year":"2021","unstructured":"Shao, Y. et al. Comprehensive metabolic profiling of Parkinson\u2019s disease by liquid chromatography-mass spectrometry. Mol. Neurodegeneration. 16, 4. https:\/\/doi.org\/10.1186\/s13024-021-00425-8 (2021).","journal-title":"Mol. Neurodegeneration"},{"key":"30521_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jchromb.2018.01.025","volume":"1081\u20131082","author":"H Zhao","year":"2018","unstructured":"Zhao, H. et al. Potential biomarkers of Parkinson\u2019s disease revealed by plasma metabolic profiling. J. Chromatogr. B. 1081\u20131082, 101\u2013108. https:\/\/doi.org\/10.1016\/j.jchromb.2018.01.025 (2018).","journal-title":"J. Chromatogr. B"},{"key":"30521_CR10","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/mds.28608","volume":"36","author":"T Kremer","year":"2021","unstructured":"Kremer, T. et al. Longitudinal analysis of multiple neurotransmitter metabolites in cerebrospinal fluid in early Parkinson\u2019s disease. Mov. Disord. 36, 1972\u20131978. https:\/\/doi.org\/10.1002\/mds.28608 (2021).","journal-title":"Mov. Disord."},{"key":"30521_CR11","doi-asserted-by":"publisher","first-page":"e0208752","DOI":"10.1371\/journal.pone.0208752","volume":"13","author":"D Willkommen","year":"2018","unstructured":"Willkommen, D. et al. Metabolomic investigations in cerebrospinal fluid of Parkinson\u2019s disease. PLoS ONE. 13, e0208752. https:\/\/doi.org\/10.1371\/journal.pone.0208752 (2018).","journal-title":"PLoS ONE"},{"key":"30521_CR12","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/mds.25555","volume":"28","author":"PA LeWitt","year":"2013","unstructured":"LeWitt, P. A. et al. 3-hydroxykynurenine and other Parkinson\u2019s disease biomarkers discovered by metabolomic analysis. Mov. Disord. 28, 1653\u20131660. https:\/\/doi.org\/10.1002\/mds.25555 (2013).","journal-title":"Mov. Disord."},{"key":"30521_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3389\/fnagi.2018.00051","volume":"10","author":"D Stoessel","year":"2018","unstructured":"Stoessel, D. et al. Promising metabolite profiles in the plasma and CSF of early clinical Parkinson\u2019s disease. Front. Aging Neurosci. 10, 51. https:\/\/doi.org\/10.3389\/fnagi.2018.00051 (2018).","journal-title":"Front. Aging Neurosci."},{"key":"30521_CR14","doi-asserted-by":"publisher","first-page":"e043233","DOI":"10.1002\/alz.043233","volume":"16","author":"L Ibanez","year":"2020","unstructured":"Ibanez, L. et al. A comprehensive analysis of dementia cerebrospinal fluid biomarkers using GWAs, polygenic risk scores and Mendelian randomization in Parkinson\u2019s disease: Genetics\/atypical and other dementias. Alzheimer\u2019s Dement. 16, e043233. https:\/\/doi.org\/10.1002\/alz.043233 (2020).","journal-title":"Alzheimer\u2019s Dement."},{"key":"30521_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41588-022-01270-1","volume":"55","author":"Y Chen","year":"2023","unstructured":"Chen, Y. et al. Genomic atlas of the plasma metabolome prioritizes metabolites implicated in human diseases. Nat. Genet. 55, 44\u201353. https:\/\/doi.org\/10.1038\/s41588-022-01270-1 (2023).","journal-title":"Nat. Genet."},{"key":"30521_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s42003-020-01583-z","volume":"4","author":"DJ Panyard","year":"2021","unstructured":"Panyard, D. J. et al. Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations. Commun. Biol. 4, 63. https:\/\/doi.org\/10.1038\/s42003-020-01583-z (2021).","journal-title":"Commun. Biol."},{"key":"30521_CR17","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091\u20131102. https:\/\/doi.org\/10.1016\/S1474-4422(19)30320-5 (2019).","journal-title":"Lancet Neurol."},{"key":"30521_CR18","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.3390\/biomedicines12061178","volume":"12","author":"A Duan","year":"2024","unstructured":"Duan, A. et al. Metabolome-wide Mendelian randomization assessing the causal role of serum and cerebrospinal metabolites in traumatic brain injury. Biomedicines 12, 1178. https:\/\/doi.org\/10.3390\/biomedicines12061178 (2024).","journal-title":"Biomedicines"},{"key":"30521_CR19","doi-asserted-by":"publisher","DOI":"10.18632\/aging.205818","author":"Z Zhou","year":"2024","unstructured":"Zhou, Z. & Leng, H. Deciphering the causal relationship between plasma and cerebrospinal fluid metabolites and glioblastoma multiforme: a Mendelian randomization study. Aging https:\/\/doi.org\/10.18632\/aging.205818 (2024).","journal-title":"Aging"},{"key":"30521_CR20","doi-asserted-by":"crossref","unstructured":"Botelho, J., Machado, V., Mendes, J. J. & Mascarenhas, P. Causal association between periodontitis and Parkinson\u2019s disease: a bidirectional Mendelian randomization study. 8 (2021).","DOI":"10.20944\/preprints202010.0145.v1"},{"key":"30521_CR21","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1002\/sim.3034","volume":"27","author":"DA Lawlor","year":"2008","unstructured":"Lawlor, D. A. et al. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Statist Med. 27, 1133\u20131163. https:\/\/doi.org\/10.1002\/sim.3034 (2008).","journal-title":"Statist Med."},{"key":"30521_CR22","doi-asserted-by":"publisher","first-page":"e34408","DOI":"10.7554\/eLife.34408","volume":"7","author":"G Hemani","year":"2018","unstructured":"Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife 7, e34408. https:\/\/doi.org\/10.7554\/eLife.34408 (2018).","journal-title":"eLife"},{"key":"30521_CR23","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/mds.28640","volume":"36","author":"MA Estiar","year":"2021","unstructured":"Estiar, M. A. et al. Lack of causal effects or genetic correlation between restless legs syndrome and Parkinson\u2019s disease. Mov. Disord. 36, 1967\u20131972. https:\/\/doi.org\/10.1002\/mds.28640 (2021).","journal-title":"Mov. Disord"},{"key":"30521_CR24","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/jcph.1008","volume":"58","author":"LD Coles","year":"2018","unstructured":"Coles, L. D. et al. Repeated-dose oral N\u2010acetylcysteine in Parkinson\u2019s disease: pharmacokinetics and effect on brain glutathione and oxidative stress. J. Clin. Pharma. 58, 158\u2013167. https:\/\/doi.org\/10.1002\/jcph.1008 (2018).","journal-title":"J. Clin. Pharma"},{"key":"30521_CR25","unstructured":"Oxenkrug, G. Peripheral tryptophan-kynurenine metabolism associated with metabolic syndrome is different in Parkinson\u2019s and Alzheimer\u2019s diseases (2017)."},{"key":"30521_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13195-020-00741-z","volume":"13","author":"on behalf of AddNeuroMed consortium","year":"2021","unstructured":"on behalf of AddNeuroMed consortium et al. Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer\u2019s disease. Alz Res. Therapy. 13, 20. https:\/\/doi.org\/10.1186\/s13195-020-00741-z (2021).","journal-title":"Alz Res. Therapy"},{"key":"30521_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40478-022-01424-6","volume":"10","author":"CE Toomey","year":"2022","unstructured":"Toomey, C. E. et al. Mitochondrial dysfunction is a key pathological driver of early stage Parkinson\u2019s. Acta neuropathol. commun. 10, 134. https:\/\/doi.org\/10.1186\/s40478-022-01424-6 (2022).","journal-title":"Acta neuropathol. commun."},{"key":"30521_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/BF02435979","volume":"15","author":"C P\u00e9rez-Cerd\u00e1","year":"1992","unstructured":"P\u00e9rez-Cerd\u00e1, C. et al. A new case of succinyl\u2010CoA: acetoacetate transferase deficiency. J. Inher Metab. Disea. 15, 371\u2013373. https:\/\/doi.org\/10.1007\/BF02435979 (1992).","journal-title":"J. Inher Metab. Disea"},{"key":"30521_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-01973-7","author":"C Wang","year":"2024","unstructured":"Wang, C. et al. Genetic architecture of cerebrospinal fluid and brain metabolite levels and the genetic colocalization of metabolites with human traits. Nat. Genet. https:\/\/doi.org\/10.1038\/s41588-024-01973-7 (2024).","journal-title":"Nat. Genet."},{"key":"30521_CR30","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1042\/bj3050993","volume":"305","author":"Y Sakakibara","year":"1995","unstructured":"Sakakibara, Y., Suiko, M., Nakajima, H. & Liu, M. C. Sulphation of l-tyrosine in mammalian cells: a comparative study. Biochem. J. 305, 993\u2013998. https:\/\/doi.org\/10.1042\/bj3050993 (1995).","journal-title":"Biochem. J."},{"key":"30521_CR31","doi-asserted-by":"publisher","first-page":"423","DOI":"10.3233\/JPD-150736","volume":"6","author":"M Hirayama","year":"2016","unstructured":"Hirayama, M. et al. Serum tyrosine-to-phenylalanine ratio is low in Parkinson\u2019s disease. J. Parkinson\u2019s Disease. 6, 423\u2013431. https:\/\/doi.org\/10.3233\/JPD-150736 (2016).","journal-title":"J. Parkinson\u2019s Disease"},{"key":"30521_CR32","doi-asserted-by":"publisher","first-page":"30271","DOI":"10.1038\/s41598-024-81787-z","volume":"14","author":"L Cheng","year":"2024","unstructured":"Cheng, L. et al. Exploring the causal link between serum amino acids and Parkinson\u2019s disease: a Mendelian randomization approach. Sci. Rep. 14, 30271. https:\/\/doi.org\/10.1038\/s41598-024-81787-z (2024).","journal-title":"Sci. Rep."},{"key":"30521_CR33","doi-asserted-by":"publisher","first-page":"E1378","DOI":"10.1152\/ajpendo.00656.2013","volume":"306","author":"JM Rutkowsky","year":"2014","unstructured":"Rutkowsky, J. M. et al. Acylcarnitines activate proinflammatory signaling pathways. Am. J. Physiology-Endocrinology Metabolism. 306, E1378\u2013E1387. https:\/\/doi.org\/10.1152\/ajpendo.00656.2013 (2014).","journal-title":"Am. J. Physiology-Endocrinology Metabolism"},{"key":"30521_CR34","doi-asserted-by":"publisher","unstructured":"Alza, N. P., Conde, M. A., Scodelaro-Bilbao, P. G. & Salvador, G. A. Neutral lipids as early biomarkers of cellular fate: the case of \u03b1-synuclein overexpression. Cell. Death Dis. 12 https:\/\/doi.org\/10.1038\/s41419-020-03254-7 (2021).","DOI":"10.1038\/s41419-020-03254-7"},{"key":"30521_CR35","doi-asserted-by":"publisher","first-page":"e0172348","DOI":"10.1371\/journal.pone.0172348","volume":"12","author":"RB Chan","year":"2017","unstructured":"Chan, R. B. et al. Elevated GM3 plasma concentration in idiopathic Parkinson\u2019s disease: A lipidomic analysis. PLoS ONE. 12, e0172348. https:\/\/doi.org\/10.1371\/journal.pone.0172348 (2017).","journal-title":"PLoS ONE"},{"key":"30521_CR36","doi-asserted-by":"publisher","unstructured":"Hu, L. et al. Integrated metabolomics and proteomics analysis reveals plasma lipid metabolic disturbance in patients with Parkinson\u2019s disease. Front. Mol. Neurosci. 13 https:\/\/doi.org\/10.3389\/fnmol.2020.00080 (2020).","DOI":"10.3389\/fnmol.2020.00080"},{"key":"30521_CR37","doi-asserted-by":"publisher","first-page":"711396","DOI":"10.3389\/fnmol.2021.711396","volume":"14","author":"M Scholefield","year":"2021","unstructured":"Scholefield, M. et al. Severe and regionally widespread increases in tissue urea in the human brain represent a novel finding of pathogenic potential in Parkinson\u2019s disease dementia. Front. Mol. Neurosci. 14, 711396. https:\/\/doi.org\/10.3389\/fnmol.2021.711396 (2021).","journal-title":"Front. Mol. Neurosci."},{"key":"30521_CR38","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3143\/geriatrics.54.560","volume":"54","author":"M Yasunishi","year":"2017","unstructured":"Yasunishi, M. et al. A case of hyperammonemia resulting from urinary tract infection caused by urease-producing bacteria in a Parkinson\u2019s disease patient with drug-induced urinary retention. Jpn j. Geriat. 54, 560\u2013566. https:\/\/doi.org\/10.3143\/geriatrics.54.560 (2017).","journal-title":"Jpn j. Geriat"},{"key":"30521_CR39","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.4103\/0028-3886.391388","volume":"71","author":"G Yang","year":"2023","unstructured":"Yang, G. et al. Study on the correlation between blood urea nitrogen, creatinine level, proteinuria and Parkinson\u2019s disease. Neurol. India. 71, 1217\u20131221. https:\/\/doi.org\/10.4103\/0028-3886.391388 (2023).","journal-title":"Neurol. India"},{"key":"30521_CR40","doi-asserted-by":"publisher","first-page":"115426","DOI":"10.1016\/j.bbr.2025.115426","volume":"482","author":"J Liao","year":"2025","unstructured":"Liao, J. et al. Causal association between cerebrospinal fluid metabolites and Parkinson\u2019s disease: A two-sample bidirectional Mendelian randomization study. Behav. Brain. Res. 482, 115426. https:\/\/doi.org\/10.1016\/j.bbr.2025.115426 (2025).","journal-title":"Behav. Brain. Res."},{"key":"30521_CR41","doi-asserted-by":"publisher","first-page":"111067","DOI":"10.1016\/j.pnpbp.2024.111067","volume":"134","author":"A Zhang","year":"2024","unstructured":"Zhang, A. et al. Causal association between plasma metabolites and neurodegenerative diseases. Prog. Neuropsychopharmacol. Biol. Psychiatry. 134, 111067. https:\/\/doi.org\/10.1016\/j.pnpbp.2024.111067 (2024).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30521-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30521-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T23:06:01Z","timestamp":1774307161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-30521-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["30521"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-30521-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical review and approval were waived for this study because no individual patients were directly involved in the overall process of our study. Our study was based only on publicly available GWAS data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Standard protocol approvals, registrations, and patient consents"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9588"}}